Patient characteristics
| Patient characteristics | Diagnosis | |
|---|---|---|
| axSpA (n=32, 60%) | PsA (n=21, 40%) | |
| Median age, years (interquartile range (IQR)) | 49 (41–58) | 57 (50–63) |
| Male:female ratio | 30:1 | 7:14 |
| Infliximab duration (years) | 11 (8–15) | 9 (6–14) |
| Median weight, kg (IQR) | 80.5 (72–93) | 76 (64–97) |
| Concomitant csDMARD, n (%) | 12 (36) | 17 (81) |
| Methotrexate, n (%), dose | 12 (100%), 15 mg/week | 16 (94%), 10 mg/week |
| Hydroxychloroquine, n (%), dose | 0 (0) | 1 (6), 200 mg/day |
| Previous bDMARD, n (%) | 5 (16) | 5 (24) |
axSpA = Axial spondyloarthritis; bDMARD = biological disease-modifying antirheumatic drug; csDMARD = conventional synthetic disease-modifying antirheumatic drug; PsA = psoriatic arthritis.